Want to join the conversation?
Mark Schoenebaum of Evercore ISI asks about the second line treatment duration. $BMY said that on the second line duration of treatment, the company needs about two years of in-market experience to determine what the company's actual duration of therapy is. So $BMY is still late on that.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.